HB3335 would require certain Illinois health insurance plans and public employee/public aid coverage to cap out-of-pocket costs for a 30-day supply of covered prescription weight loss drugs at no more than $200 for plans amended, delivered, issued, or renewed on or after January 1, 2026. The bill applies this cap across a broad set of coverage arrangements, including individual and group accident and health plans, managed care plans, the State Employees Group Insurance Act, county and municipal self-insurance plans, school employee coverage, HMOs, limited health service organizations, voluntary health services plans, and Medicaid.
The bill also gives the Illinois Department of Insurance rulemaking and enforcement authority to implement the new requirement. It states that insurers may choose to reduce cost sharing by more than the statutory cap, and it includes an annual inflation adjustment tied to the medical care component of the Consumer Price Index for the insulin-related cost-sharing limit referenced in the bill text. The measure is framed as an amendment to multiple insurance and public benefit statutes, effectively adding a new mandated benefit/cost-sharing rule across Illinois-regulated health coverage.
HB3335 would amend the Illinois Insurance Code and several related statutes to impose a new cost-sharing ceiling for prescription weight loss drugs, expanding the mandate beyond commercial insurance to state, local government, school, HMO, limited health service, voluntary health services, and Medicaid coverage. In practical terms, insurers and public programs would need to update benefit designs, claims processing, and compliance procedures for plans renewed or issued after the effective date. The Department of Insurance would gain enforcement and rulemaking authority, and the bill would create a new statutory coverage requirement that could increase plan costs and reduce out-of-pocket expenses for affected enrollees.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, support, or opposition in the available materials. Based on the bill’s structure, the measure appears consumer-protective and aimed at improving affordability for patients using prescription weight loss medications. The absence of voting history or hearing testimony means overall sentiment cannot be measured from the record provided.
The main likely point of contention is cost: insurers, public employers, and Medicaid administrators may object to a mandated $200 cap because it could shift more spending to plans and public programs. Another possible issue is scope, since the bill applies the requirement broadly across many coverage types and includes drugs such as Ozempic, Wegovy, and Mounjaro, which are often associated with high utilization and significant plan expense. There may also be technical drafting concerns in the bill text, including the way it describes “prescription weight loss drugs” and references insulin-related indexing language, which could prompt questions about clarity and implementation.